Sue Desmond-Hell­mann joins Pfiz­er board; Kite Phar­ma taps al­ly in push to ex­pand CAR-T

Sue Desmond-Hell­mann will be join­ing Pfiz­er’s board of di­rec­tors, four months af­ter step­ping down as CEO of the Bill and Melin­da Gates Foun­da­tion. The Amer­i­can phar­ma gi­ant has at­tract­ed a star-stud­ded board, most re­cent­ly adding Co­ca-Co­la CEO James Quincey and for­mer FDA chief Scott Got­tlieb. Desmond-Hell­man is no ex­cep­tion, hav­ing spent years at the top of Genen­tech, where she helped pi­o­neer the first tar­get­ed can­cer drugs, and serv­ing as the first woman chan­cel­lor of the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co be­fore join­ing the foun­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.